Stewart Craig, Ph.D.
Chief Technical Officer and Vice President
scraig@progenitorcelltherapy.com

Dr. Craig joined Progenitor Cell Therapy, LLC as Chief Technology Officer & Vice President in July 2005. Prior to joining PCT, Dr. Craig served as Chief Operating Officer at Xcyte Therapies, Inc., a company developing T cell-based therapeutic products for the treatment of cancer, immune dysfunction and other diseases. Over the course of six (6) years at Xcyte Therapies, Dr. Craig designed, built, validated and operated both pilot-scale and commercial-scale facilities for the GMP manufacture of T-cell based products and managed the departments responsible for process development, assay methods development, manufacturing operations, quality control, quality assurance, regulatory affairs and external contract manufacturing of antibodies and antibody coated beads. Dr. Craig was also responsible for various business development activities in the US, Europe and Asia and participated in the multiple private and public funding efforts of Xcyte Therapies, including the S1 compilation, the successful IPO road show and the subsequent secondary public offering road show.

Prior to joining Xcyte Therapies, Dr. Craig served as Vice President, Development & Operations at Osiris Therapeutics the Baltimore-based mesenchymal stem cell therapy company. In this role Dr. Craig built the development and manufacturing infra-structure for Osiris that was integral to the initiation of clinical trials, including the design, construction, validation and operation of a pilot-scale GMP manufacturing facility. Designs for a commercial-scale GMP manufacturing facility were also successfully presented and vetted by FDA. During this time Dr. Craig was also a member of the United States Pharmacopeia Expert Advisory Panel for Cell and Gene Therapy and was a co-authored for the initial USP monograph on this subject.

From 1994 - 1996, Dr. Craig served as Vice President Product & Process Development at SyStemix, Inc., the pioneering Califonia-based hematopoietic stem cell and gene therapy company. From 1987 – 1993, Dr. Craig served in various research and development positions at British Biotech, PLC, working on the design, purification and characterization of recombinant therapeutic protein molecules. Dr. Craig received his B.Sc. in Biochemistry and Ph.D. in Physical Biochemistry from the University of Newcastle upon Tyne, UK.